Got $300? 2 Biotech Stocks to Buy and Hold Forever

Core Insights - Krystal Biotech and ARS Pharmaceuticals are gaining attention due to their unique therapies with blockbuster potential [1][2] Krystal Biotech - Krystal Biotech has developed Vyjuvek, the first topical genetic therapy approved by the FDA for dystrophic epidermolysis bullosa, a rare skin disorder [2] - The company is working on expanding the labels for Vyjuvek while using its growing revenues to fund its pipeline [3] - Krystal's KB707 candidate is aimed at treating advanced or metastatic non-small cell lung cancer and has received a Regenerative Medicine Advanced Therapy designation from the FDA [6] - Preliminary sales for Vyjuvek are expected to reach $388 million to $389 million, indicating a 34% increase at the midpoint [7] - Analysts predict annual EPS for Krystal will be between $6.46 and $8.92, a 156% increase over the prior year at the midpoint [8] - The stock has increased over 10% year to date and nearly 80% over the past year, currently trading around $270 per share [8] ARS Pharmaceuticals - ARS Pharma focuses on preventing allergic reactions that can lead to anaphylaxis, with its product Neffy being the first non-injection epinephrine treatment approved by the FDA [2][9] - The company has faced challenges with the FDA regarding its advertising for Neffy, which was deemed misleading [11] - ARS Pharma's stock has decreased over 24% year to date and over the past 12 months, indicating a riskier investment compared to Krystal Biotech [12] - Revenue for ARS Pharma reached $51.8 million in the first nine months of 2025, a significant increase from $568,000 in the same period in 2024 [13] - The global market size for epinephrine is projected to be $2.48 billion in 2025, highlighting ARS Pharma's growth potential [13] - ARS Pharma is also looking to expand indications for Neffy and has a pipeline candidate, ARS-2, for treating chronic urticaria [14]